Jim Hassard appointed as CCO at Aligos Therapeutics

Home / Company news / Jim Hassard appointed as CCO at Aligos Therapeutics

Congratulations to our client Aligos Therapeutics for appointing Jim Hassard as Chief Commercial Officer

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

C1 Team: Evan Fishel, Christos Richards, and James Reynolds

Author